Published in J Rheumatol on August 01, 2004
Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum (2008) 19.80
Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev (2006) 3.27
Genome-wide association analyses identify 18 new loci associated with serum urate concentrations. Nat Genet (2012) 3.04
Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005. Ann Rheum Dis (2007) 2.89
Uric acid transport and disease. J Clin Invest (2010) 2.33
The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther (2010) 2.07
Update on gout: new therapeutic strategies and options. Nat Rev Rheumatol (2010) 2.02
Epidemiology of gout. Arthritis Res Ther (2010) 1.99
Quality of care for gout in the US needs improvement. Arthritis Rheum (2007) 1.93
Epidemiology, risk factors, and lifestyle modifications for gout. Arthritis Res Ther (2006) 1.80
Patients and providers view gout differently: a qualitative study. Chronic Illn (2010) 1.60
Association of common polymorphisms in GLUT9 gene with gout but not with coronary artery disease in a large case-control study. PLoS One (2008) 1.51
Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney. Arthritis Res Ther (2016) 1.40
Sex differences in gout epidemiology: evaluation and treatment. Ann Rheum Dis (2006) 1.39
Uric acid, hyperuricemia and vascular diseases. Front Biosci (Landmark Ed) (2012) 1.38
Epidemiology of gout. Rheum Dis Clin North Am (2014) 1.28
Developments in the scientific and clinical understanding of gout. Arthritis Res Ther (2008) 1.26
Risk factors for gout and prevention: a systematic review of the literature. Curr Opin Rheumatol (2011) 1.23
Treating gout with pegloticase, a PEGylated urate oxidase, provides insight into the importance of uric acid as an antioxidant in vivo. Proc Natl Acad Sci U S A (2010) 1.23
Patients' knowledge and beliefs concerning gout and its treatment: a population based study. BMC Musculoskelet Disord (2012) 1.15
Management of hyperuricemia in gout: focus on febuxostat. Clin Interv Aging (2010) 1.14
Gout--current diagnosis and treatment. Dtsch Arztebl Int (2009) 1.14
Serum uric acid is associated with carotid plaques: the National Heart, Lung, and Blood Institute Family Heart Study. J Rheumatol (2009) 1.11
The prevalence of rheumatic diseases in central Greece: a population survey. BMC Musculoskelet Disord (2010) 1.07
The epidemiology of uric acid and fructose. Semin Nephrol (2011) 1.06
Are either or both hyperuricemia and xanthine oxidase directly toxic to the vasculature? A critical appraisal. Arthritis Rheum (2012) 1.00
Prevalence of hyperuricemia and its related risk factors in healthy adults from Northern and Northeastern Chinese provinces. BMC Public Health (2013) 0.97
Trends in physician diagnosed gout and gout therapies in the US: results from the national ambulatory health care surveys 1993 to 2009. Arthritis Res Ther (2013) 0.95
Chronic kidney disease in gout in a managed care setting. BMC Nephrol (2011) 0.93
Prevalence of hyperuricemia in Bangkok population. Clin Rheumatol (2011) 0.93
The association of dietary intake of purine-rich vegetables, sugar-sweetened beverages and dairy with plasma urate, in a cross-sectional study. PLoS One (2012) 0.92
Participation of women and sex analyses in late-phase clinical trials of new molecular entity drugs and biologics approved by the FDA in 2007-2009. J Womens Health (Larchmt) (2013) 0.91
[Full version of the S2e guidelines on gouty arthritis : Evidence-based guidelines of the German Society of Rheumatology (DGRh)]. Z Rheumatol (2016) 0.91
Gout: a review of nonmodifiable and modifiable risk factors. Rheum Dis Clin North Am (2014) 0.90
Systematic review and meta-analysis of the clinical efficacy and adverse effects of Chinese herbal decoction for the treatment of gout. PLoS One (2014) 0.90
Gout. Novel therapies for treatment of gout and hyperuricemia. Arthritis Res Ther (2009) 0.90
Effectiveness of a pharmacist-based gout care management programme in a large integrated health plan: results from a pilot study. BMJ Open (2014) 0.89
A genome wide association study of plasma uric acid levels in obese cases and never-overweight controls. Obesity (Silver Spring) (2013) 0.89
An update on the pathology and clinical management of gouty arthritis. Clin Rheumatol (2011) 0.88
Validity of gout diagnosis in Swedish primary and secondary care - a validation study. BMC Musculoskelet Disord (2015) 0.87
Elderly-onset gout: a review. Rheumatol Int (2007) 0.87
Remembering the forgotten non-communicable diseases. BMC Med (2014) 0.85
Large epidemiologic studies of gout: challenges in diagnosis and diagnostic criteria. Curr Rheumatol Rep (2011) 0.84
Prevalence of hyperuricemia and its correlates in rural Northeast Chinese population: from lifestyle risk factors to metabolic comorbidities. Clin Rheumatol (2015) 0.83
The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age. BMC Geriatr (2012) 0.82
Risk factors for gout developed from hyperuricemia in China: a five-year prospective cohort study. Rheumatol Int (2012) 0.81
Low-dose aspirin use and recurrent gout attacks. Ann Rheum Dis (2013) 0.81
African American patients with gout: efficacy and safety of febuxostat vs allopurinol. BMC Musculoskelet Disord (2012) 0.81
Interleukin-1 antagonism in acute gout: is targeting a single cytokine the answer? Arthritis Rheum (2010) 0.81
Body mass index and the risk of gout: a systematic review and dose-response meta-analysis of prospective studies. Eur J Nutr (2014) 0.81
"Clinical features of women with gout arthritis." A systematic review. Clin Rheumatol (2010) 0.81
Relationship between uric acid and blood pressure in different age groups. Clin Hypertens (2015) 0.81
Gout after living kidney donation: correlations with demographic traits and renal complications. Am J Nephrol (2015) 0.80
Association between Dietary Magnesium Intake and Hyperuricemia. PLoS One (2015) 0.80
The prevalence of hyperuricemia and its correlates in an inland Chinese adult population, urban and rural of Jinan. Rheumatol Int (2012) 0.80
Adherence and persistence to urate-lowering therapies in the Irish setting. Clin Rheumatol (2014) 0.80
[New knowledge on the pathophysiology and therapy of gout]. Z Rheumatol (2007) 0.79
Pharmacokinetics and pharmacodynamics of febuxostat under fasting conditions in healthy individuals. Exp Ther Med (2013) 0.78
Gout in Older Adults: The Atherosclerosis Risk in Communities Study. J Gerontol A Biol Sci Med Sci (2015) 0.78
Spinal gout mimicking paraspinal abscess: A case report. J Radiol Case Rep (2010) 0.78
Guava leaves polyphenolics-rich extract inhibits vital enzymes implicated in gout and hypertension in vitro. J Intercult Ethnopharmacol (2016) 0.77
Association of maximum weight with hyperuricemia risk: a retrospective study of 21,414 Chinese people. PLoS One (2012) 0.77
Serum uric acid and disorders of glucose metabolism: the role of glycosuria. Braz J Med Biol Res (2014) 0.77
Can racial disparities in optimal gout treatment be reduced? Evidence from a randomized trial. BMC Med (2012) 0.76
The rising prevalence and incidence of gout in British Columbia, Canada: Population-based trends from 2000 to 2012. Semin Arthritis Rheum (2016) 0.76
Association between the hypertriglyceridemic waist phenotype and hyperuricemia: a cross-sectional study. Clin Rheumatol (2017) 0.76
The inflammasome as a target for pain therapy. Br J Anaesth (2016) 0.76
The epidemiology and treatment of gout. Open Access Rheumatol (2011) 0.75
Higher blood hematocrit predicts hyperuricemia: a prospective study of 62,897 person-years of follow-up. Sci Rep (2015) 0.75
Disease Control, Health Resource Use, Healthcare Costs, and Predictors in Gout Patients in the United States, the United Kingdom, Germany, and France: A Retrospective Analysis. Rheumatol Ther (2016) 0.75
TT genotype of rs2941484 in the human HNF4G gene is associated with hyperuricemia in Chinese Han men. Oncotarget (2017) 0.75
Febuxostat: a novel agent for management of hyperuricemia in gout. Indian J Pharm Sci (2011) 0.75
Cichorium intybus L. promotes intestinal uric acid excretion by modulating ABCG2 in experimental hyperuricemia. Nutr Metab (Lond) (2017) 0.75
Is tea consumption associated with the serum uric acid level, hyperuricemia or the risk of gout? A systematic review and meta-analysis. BMC Musculoskelet Disord (2017) 0.75
Pharmacokinetics and Bioequivalence of Two Formulations of Febuxostat 40-Mg and 80-Mg Tablets: A Randomized, Open-Label, 4-Way Crossover Study in Healthy Chinese Male Volunteers. PLoS One (2016) 0.75
Prevalence and incidence of gout in southern Sweden from the socioeconomic perspective. RMD Open (2016) 0.75
Plasma Levels of Uric Acid, Urea and Creatinine in Diabetics Who Visit the Clinical Analysis Laboratory (CAn-Lab) at Kwame Nkrumah University of Science and Technology, Kumasi, Ghana. J Clin Diagn Res (2015) 0.75
Pegloticase for treatment of tophaceous polyarticular gout. Hawaii J Med Public Health (2013) 0.75
Total saponins from Discorea nipponica makino ameliorate urate excretion in hyperuricemic rats. Pharmacogn Mag (2015) 0.75
Gouty arthritis at interphalangeal joint of foot after sildenafil use: A case report. Int J Surg Case Rep (2012) 0.75
An old disease with new insights: Update on diagnosis and treatment of gout. Eur J Rheumatol (2014) 0.75
Diagnosis and Treatment of Acute Gout at a University Hospital Emergency Department. Open Rheumatol J (2015) 0.75
The Association Between Hyperuricemia and Hematological Indicators in a Chinese Adult Population. Medicine (Baltimore) (2016) 0.75
Predictive Validity of the Beers and Screening Tool of Older Persons' Potentially Inappropriate Prescriptions (STOPP) Criteria to Detect Adverse Drug Events, Hospitalizations, and Emergency Department Visits in the United States. J Am Geriatr Soc (2016) 0.75
Efficacy and safety of ozonated autohemotherapy in patients with hyperuricemia and gout: A phase I pilot study. Exp Ther Med (2014) 0.75
Hypouricemic and arthritis relapse-reducing effects of compound tufuling oral-liquid in intercritical and chronic gout: A double-blind, placebo-controlled, multicenter randomized trial. Medicine (Baltimore) (2017) 0.75
Thoracic cord compression due to ligamentum flavum gouty tophus: a case report and literature review. Spinal Cord (2015) 0.75
Prevalence of calcified carotid artery atheromas on panoramic images of older men with gout: a descriptive retrospective study. Dentomaxillofac Radiol (2017) 0.75
Prioritizing Future Research on Allopurinol and Febuxostat for the Management of Gout: Value of Information Analysis. Pharmacoeconomics (2017) 0.75
Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med (2005) 7.24
Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum (2008) 3.25
Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum (2005) 1.70
Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims. J Rheumatol (2004) 1.52
Direct costs of chronic obstructive pulmonary disease among managed care patients. Int J Chron Obstruct Pulmon Dis (2010) 1.40
Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment. Am J Ther (2005) 1.36
Effect of food or antacid on pharmacokinetics and pharmacodynamics of febuxostat in healthy subjects. Br J Clin Pharmacol (2007) 1.21
The economic burden of gout on an employed population. Curr Med Res Opin (2006) 1.20
The impact of gout on work absence and productivity. Value Health (2007) 1.10
Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects. Clin Pharmacokinet (2006) 1.04
The effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase. J Clin Pharmacol (2006) 1.03
Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy. Nucleosides Nucleotides Nucleic Acids (2008) 0.99
The effect of age and gender on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase. J Clin Pharmacol (2008) 0.95
Economic burden prior to COPD diagnosis: a matched case-control study in the United States. Respir Med (2008) 0.95
Chronic kidney disease in gout in a managed care setting. BMC Nephrol (2011) 0.93
Prevalence of comorbid conditions and prescription medication use among patients with gout and hyperuricemia in a managed care setting. J Clin Rheumatol (2004) 0.93
Outcome measures for acute and chronic gout. J Rheumatol (2005) 0.91
Tophaceous gout: quantitative evaluation by direct physical measurement. J Rheumatol (2005) 0.88
Pharmacokinetic interactions of concomitant administration of febuxostat and NSAIDs. J Clin Pharmacol (2006) 0.85
Relationship between physician specialty and allopurinol prescribing patterns: a study of patients with gout in managed care settings. Curr Med Res Opin (2011) 0.84
Outcome evaluations in gout. J Rheumatol (2007) 0.82
Cost trends among commercially insured and Medicare Advantage-insured patients with chronic obstructive pulmonary disease: 2006 through 2009. Int J Chron Obstruct Pulmon Dis (2011) 0.80
Patterns of asthma-related health care resource use in children treated with montelukast or fluticasone. Curr Med Res Opin (2006) 0.80
Observational study of the effects of using montelukast vs fluticasone in patients matched at baseline. Ann Allergy Asthma Immunol (2004) 0.80
Comparative resource utilization in medicaid-eligible patients with asthma treated with fixed-dose fluticasone propionate/salmeterol or fluticasone propionate monotherapy. Clin Ther (2010) 0.78
Five-year routine cervical cancer screening rates and intervals in a US health plan. Curr Med Res Opin (2008) 0.78
Metabolic syndrome-related conditions among people with and without gout: prevalence and resource use. Curr Med Res Opin (2007) 0.77
Role of indomethacin in acute pain and inflammation management: a review of the literature. Postgrad Med (2014) 0.76
Idiopathic inflammatory myopathies-a review. Clin Rheumatol (2015) 0.76
Asthma controller delay and recurrence risk after an emergency department visit or hospitalization. Respir Med (2012) 0.75